Skip to main content
Clinical Trials/NCT03392662
NCT03392662
Completed
Not Applicable

Hemopatch Performance Evaluation: A Prospective Observational Registry

Baxter Healthcare Corporation15 sites in 5 countries621 target enrollmentNovember 29, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Dura Mater Nick Cut or Tear
Sponsor
Baxter Healthcare Corporation
Enrollment
621
Locations
15
Primary Endpoint
Number of patients with postoperative pancreatic fistulas after hepatobiliary surgery
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

To assess the clinical performance and safety of HEMOPATCH Sealing Hemostat in a post-marketing setting in cardiovascular, thoracic, urologic, neurological, and other general surgical procedures.

Registry
clinicaltrials.gov
Start Date
November 29, 2017
End Date
January 28, 2019
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female patients of any age
  • Patients who had undergone open or minimal invasive surgical (MIS) procedures requiring the use of a patch to achieve dura repair, hemostasis, or control of leakage of air or other body fluid when pressure, ligature or other conventional procedures had been ineffective or impractical and where use of hemopatch was deemed appropriate by the surgeon according to its IFU in the following organ systems:
  • Hepato-biliary (liver, pancreas, gallbladder)
  • General surgery (in thyroid and other regions)
  • Cardiovascular (heart and vessels)
  • thoracic (lung and mediastinum)
  • Urological (kidney, prostate, and bladder
  • Neurological (dura mater, brain and spinal cord)
  • Provision of written informed consent/assent, as applicable, up to 72 hours after the date of surgery

Exclusion Criteria

  • Patients with known hypersensitivity to bovine proteins or brilliant blue
  • Patients who had intraoperative pulsatile or severe bleeding at the target application site (TAS)
  • Patients who had an active infection at the TAS

Outcomes

Primary Outcomes

Number of patients with postoperative pancreatic fistulas after hepatobiliary surgery

Time Frame: Up to 4 weeks (postoperative)

Number of patients with related Adverse Events

Time Frame: Up to 4 weeks (postoperative)

Number of patients with chest tube drainage >=5 days after thoracic/lung surgery

Time Frame: Day 5 up to 4 weeks (postoperative)

Number of patients needing reinsertion of chest tube for pneumothorax after thoracic/lung surgery

Time Frame: Up to 4 weeks (postoperative)

Duration of bile leakage after hepatobiliary surgery

Time Frame: Up to 4 weeks (postoperative)

Number of patients with postoperative cerebrospinal fluid (CSF) leakage after neurological surgery

Time Frame: Up to 4 weeks (postoperative)

External or internal accumulation including pseudomeningocele

Tight closure achieved in dura mater at time of surgical closure

Time Frame: Day 1 (intraoperative)

No leak after inspection per local standard of care

Percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure

Time Frame: Day 1 (intraoperative)

Absence of air leak in lung at time of surgical closure

Time Frame: Day 1 (intraoperative)

Number of patients with postoperative urinary fistula formation after urological surgery

Time Frame: Up to 4 weeks (postoperative)

Gastrointestinal anastomosis leakage/fistula after general surgery

Time Frame: Up to 4 weeks (postoperative)

Percentage of patients achieving hemostasis after 2 minutes of surgery

Time Frame: Day 1 (up to 2 minutes postoperative)

Secondary Outcomes

  • Number of Hemopatch units applied(Up to 4 weeks (postoperative))
  • Number of intraoperative transfusions by type and amount of blood product transfused(Day 1 (intraoperative))
  • Assessment of product tissue adherence(Day 1 (intraoperative))
  • Product characteristics liked least by Surgeon(Day 1 (intraoperative))
  • Surgery duration(Day 1 (intraoperative))
  • Length of hospital stay(Up to 4 weeks (postoperative))
  • Ease of product preparation(Day 1 (intraoperative))
  • Ease of product handling(Day 1 (intraoperative))
  • Surgeon's overall satisfaction of product(Day 1 (intraoperative))
  • Product characteristics appreciated by Surgeon(Day 1 (intraoperative))
  • Surgical revisions/reoperations due to bleeding, air, or other body fluid leakage(Up to 4 weeks (postoperative))
  • Number of postoperative transfusions by type and amount of blood product transfused up to 72 hours after surgery(Up to 72 hours (postoperative))

Study Sites (15)

Loading locations...

Similar Trials